Table 1.
Background characteristics of the patients.
| Clinical factor | Number of patients |
|---|---|
| Biographic data | |
| Age | 72.2 ± 10.0 years |
| Sex (male) | 448 (68.1%) |
| Weight | 63.0 ± 13.9 kg |
| Serum creatinine | 0.95 ± 0.31 mg/dl |
| CHADS2 score | 2.5 ± 1.2 |
| HAS-BLED score | 2.1 ± 0.9 |
| NOAC | |
| Dabigatran | 220 (33.4%) |
| Rivaroxaban | 283 (43.0%) |
| Apixaban | 155 (22.8%) |
| Past history | |
| GIB | 7 (1.1%) |
| Digestive ulcer | 25 (3.8%) |
| Cerebral infarction | 92 (14.0%) |
| Coexistent disease | |
| Hypertension | 553 (84.0%) |
| Diabetes mellitus | 167 (25.4%) |
| Dyslipidemia | 295 (44.8%) |
| Chronic heart failure | 403 (61.2%) |
| Malignant diseases | 64 (9.7%) |
| Concomitant agent | |
| Low dose aspirin | 127 (19.3%) |
| Thienopyridine | 68 (10.3%) |
| Dual antiplatelet | 28 (4.3%) |
| NSAIDs | 13 (2.0%) |
| Steroids | 30 (4.6%) |
| Diuretics | 165 (25.1%) |
| BP | 16 (2.4%) |
| PPI | 313 (47.6%) |
| H2RA | 39 (5.9%) |
| MP | 46 (7.0%) |
NOAC: nonvitamin K oral anticoagulant, GIB: gastrointestinal bleeding, NSAID: nonsteroidal anti-inflammatory drugs, BP: bisphosphonate, PPI: proton pump inhibitor, H2RA: histamine 2 receptor antagonist, and MP: mucoprotective agent.